Vitamin K and Blood Clotting: K1 vs K2 Explained

Vitamin K1 vs K2: Forms, Sources, and Functions

Vitamin K is the collective name for a family of structurally related fat-soluble vitamins sharing a 2-methyl-1,4-naphthoquinone ring structure but differing in the length and saturation of their side chains. The two nutritionally significant forms are vitamin K1 (phylloquinone) and vitamin K2 (menaquinone). K1 is synthesized exclusively in plants as a component of the photosynthetic electron transport chain; K2 is produced by bacteria (including gut bacteria) and found primarily in fermented foods and animal products.

K2 encompasses a family of subtypes designated by the number of isoprenoid units in their side chain — MK-4 through MK-13 are the most biologically relevant. MK-4 has a short side chain and is the predominant form in animal tissues (particularly liver and dairy fat); it is also produced endogenously in humans through conversion of K1 or MK-7. MK-7 has a long side chain and is found in highest concentrations in natto (a fermented soybean product) and to a lesser extent in aged cheeses. MK-7 has a significantly longer half-life in the circulation (approximately 72 hours versus 1–2 hours for K1 and MK-4), which may explain its superior bioactivity in some contexts.

While both K1 and K2 activate the same gamma-carboxylation reaction (the process by which vitamin K-dependent proteins are activated), their tissue distribution differs meaningfully. K1 is preferentially taken up by the liver for coagulation factor synthesis. K2 — particularly the longer-chain forms — distributes more broadly to extrahepatic tissues including bone, vasculature, and kidneys, where it activates additional vitamin K-dependent proteins such as osteocalcin and matrix Gla protein (MGP) that regulate bone mineralization and vascular calcification, respectively.

Blood Coagulation Cascade and Clotting Factors

Vitamin K is required for the post-translational activation of four clotting factors (II/prothrombin, VII, IX, and X) and two anticoagulant proteins (protein C and protein S) in the coagulation cascade. The activation process is called gamma-carboxylation: vitamin K-dependent carboxylase adds a carboxyl group to specific glutamate residues in these proteins, converting them to gamma-carboxyglutamate (Gla) residues that can bind calcium and thereby interact with phospholipid membranes where coagulation occurs.

Without adequate vitamin K, these clotting factors circulate in an undercarboxylated (inactive) form — called PIVKA (Proteins Induced by Vitamin K Absence). Prothrombin time (PT) and the derived INR (International Normalized Ratio) are the standard clinical measures of vitamin K-dependent coagulation; an elevated INR indicates impaired clotting, which manifests clinically as easy bruising, prolonged bleeding from wounds, and potentially serious hemorrhage. Vitamin K deficiency sufficient to impair coagulation is rare in healthy adults eating a varied diet but occurs in newborns (who are given a prophylactic vitamin K injection at birth), individuals with fat malabsorption, and patients on long-term antibiotics that eliminate gut bacteria producing K2.

The coagulation-anticoagulation balance is worth noting: protein C and protein S are also vitamin K-dependent but function as anticoagulants, inhibiting the coagulation cascade. This means that in vitamin K deficiency, both clotting and anticoagulant proteins are reduced simultaneously. The net effect is typically a procoagulant state (because the procoagulant factors are more numerous and the reduction in protein C/S is physiologically significant), explaining the hemorrhagic manifestations of deficiency.

Vitamin K2 and Bone Mineral Density

Beyond coagulation, vitamin K2 plays a critical role in skeletal mineralization through its activation of osteocalcin — a protein produced by osteoblasts that, when fully gamma-carboxylated by vitamin K, binds hydroxyapatite in the bone matrix and anchors calcium into bone tissue. Undercarboxylated osteocalcin (ucOC) cannot bind to bone mineral matrix and is released into circulation instead. High circulating ucOC is a biomarker of both vitamin K deficiency and increased fracture risk, independent of bone mineral density.

Multiple large observational studies link higher vitamin K2 intake to lower hip fracture risk. The most compelling data come from Japan, where natto consumption (extraordinarily high in MK-7) is common in eastern regions but virtually absent in western regions — and hip fracture rates are substantially lower in natto-consuming populations. The Nurses' Health Study found that women consuming vitamin K1 below the median had a 30% higher hip fracture risk compared to those above the median. Several randomized controlled trials — particularly with MK-4 in doses of 45 mg/day used in Japanese clinical practice — show significant reductions in vertebral fracture rates.

The synergy between vitamins K2 and D3 is clinically relevant: vitamin D3 stimulates osteocalcin production, and vitamin K2 ensures that this osteocalcin is fully carboxylated and therefore functional. Supplementing D3 without adequate K2 may increase osteocalcin production but leave it undercarboxylated — potentially worsening the ratio of carboxylated to undercarboxylated osteocalcin. Matrix Gla protein (MGP), another K2-dependent protein, prevents calcification of arterial walls; insufficient K2 activation of MGP is hypothesized to contribute to vascular calcification — linking vitamin K2 status to cardiovascular as well as skeletal health.

Warfarin Interactions and Dietary Consistency

Warfarin (Coumadin) is a vitamin K antagonist — it inhibits the vitamin K epoxide reductase enzyme (VKOR), preventing recycling of vitamin K to its active form and thereby reducing the activity of vitamin K-dependent coagulation factors. The therapeutic goal is to impair coagulation to a targeted degree (INR typically 2.0–3.0 for most indications) to prevent thromboembolic events. Because dietary vitamin K competes with warfarin's mechanism of action, fluctuating vitamin K intake is the primary cause of INR instability in anticoagulated patients.

The management principle is dietary consistency, not elimination. Patients on warfarin do not need to avoid vitamin K-rich foods; they need to consume consistent amounts from week to week. Dramatic increases in vitamin K intake (for example, suddenly eating very large amounts of kale every day) will reduce warfarin's effect and lower the INR (increased clotting risk). Dramatic decreases (for example, stopping all vegetables while ill) will potentiate warfarin and elevate the INR (increased bleeding risk). Educating patients that consistency is the goal — not avoidance — improves both dietary quality and INR stability.

Several drugs interact with vitamin K beyond warfarin, including other anticoagulants and antibiotics. Long-term broad-spectrum antibiotic use reduces gut bacterial synthesis of MK-7, modestly decreasing one source of vitamin K2. Cholestyramine and other bile acid sequestrants reduce fat-soluble vitamin absorption including vitamin K. Mineral oil (used as a laxative) significantly impairs fat-soluble vitamin absorption. Patients on any of these medications chronically warrant monitoring of vitamin K status if there are nutritional or clinical concerns.

Best Dietary Sources of K1 and K2

Vitamin K1 (phylloquinone) is found almost exclusively in green plants where it functions as part of the photosynthetic apparatus in chloroplasts. The richest sources are dark leafy greens: cooked kale provides approximately 1,062 mcg per cup; cooked collard greens provide 1,059 mcg per cup; cooked spinach provides 888 mcg per cup; and raw parsley provides 984 mcg per cup. These foods alone can provide more than 10 times the Adequate Intake (AI) of 90–120 mcg/day for adults in a single serving. Other significant K1 sources include broccoli (220 mcg per cooked cup), Brussels sprouts (219 mcg per cooked cup), and romaine lettuce (57 mcg per cup).

Vitamin K2 (menaquinone) food sources are more limited but critically include: natto — a Japanese fermented soybean product — which is by far the richest source, providing approximately 850–1,000 mcg MK-7 per 100 g serving (substantially more than the AI). Hard and soft cheeses (Gouda, Brie, Edam) provide 50–80 mcg per 100 g primarily as MK-8 and MK-9. Egg yolks provide approximately 32 mcg per 100 g as MK-4. Chicken dark meat provides approximately 10 mcg MK-4 per 100 g. Butter and cream provide small but meaningful amounts of MK-4.

Since vitamin K is fat-soluble, it requires dietary fat for absorption. Eating K1-rich vegetables with olive oil dressing, avocado, or other fat sources significantly enhances absorption compared to consuming them with a fat-free dressing. The typical bioavailability of K1 from raw vegetables is approximately 15–20%; cooking and consuming with fat can increase this to 30–40%. K2 from animal and fermented food sources tends to be more bioavailable due to its incorporation into lipid-rich matrices.